Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
China
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui Pecking Union Medical College Hospital, Beijing, Beijing Municipality Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing Municipality Beijing Tiantan Hospital, Captal Medical University, Beijing, Beijing Municipality Beijing Cancer Hospital, Beijing, Beijing Municipality Peking University Third Hospital, Beijing, Beijing Municipality Beijing Chest Hospital, Capital Medical University, Beijing, Beijing Municipality Fujian cancer Hospital, Fuzhou, Fujian The First Affiliated Hospital Xiamen University, Xiamen, Fujian The first Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Zhujiang Hospital of Southem Medical University, Guangzhou, Guangdong Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center, Shenzhen, Guangdong Harbin Medical University Cancer Hospital-Mammary gland of internal, Harbin, Heilongjiang Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hosipital Of Zhengzhou University, Zhengzhou, Henan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei Tongji Hospital Tongji Medical College of Hust, Wuhan, Hubei Renmin Hospital Of Wuhan University, Wuhan, Hubei Xiangya Hospital Central South Univesity, Changsha, Hunan Hunan Cancer Hospital, Changsha, Hunan The First Hospital Of China Medical University, Shenyang, Liaoning The Affilated Hospital of Inner Mongolia Medical University, Hohhot, Neimenggu Qilu Hospital of Shandong University, Jinan, Shandong Shandong Cancer Hospital, Jinan, Shandong LinYi Cancer Hospital, Linyi, Shandong Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality The Second Affiliated Hospital Zhejiang School of Medicine, Hangzhou, Zhejiang